Daxor (DXR) ROC (Joel Greenblatt) %: % (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DXR Daxor Corp DXR
47 GF Score
Price $10.20
GF Value $37.53
Valuation Possible Value Trap
! 1 Warning Sign
View Full Analysis

What is Daxor ROC (Joel Greenblatt) %?

Daxor DXR +5.48% 47 ROC (Joel Greenblatt) % is % as of Dec. 2025. GuruFocus rates DXR with a GF Score™ of 47/100 and a GF Value™ of $37.53 (Possible Value Trap). The stock has 1 warning sign investors should review. Among 837 Medical Devices & Instruments companies, Daxor ranks worse than 119474.19% on this metric.

ROC (Joel Greenblatt) % does not apply to banks and insurance companies.

DXR
47GF Score
Daxor Corp DXR
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a ROC (Joel Greenblatt) % of % mean?
Daxor (DXR) has a ROC (Joel Greenblatt) % of % as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Daxor and its competitors. According to the industry distribution chart, Daxor ranks #999999 out of 837 companies in the Medical Devices & Instruments industry.
Is Daxor's ROC (Joel Greenblatt) % too high?
Daxor's current ROC (Joel Greenblatt) % is %. Based on the distribution chart, Daxor ranks #999999 out of 837 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Daxor has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Daxor's ROC (Joel Greenblatt) % compare to POCI and NEPH?
According to the Medical Devices & Instruments industry distribution chart, Daxor ranks #999999 out of 837 companies for ROC (Joel Greenblatt) %. This places Daxor in the lower half of its industry. The industry median ROC (Joel Greenblatt) % is 5.08. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median ROC (Joel Greenblatt) % among Medical Devices & Instruments companies is 5.08, based on 837 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Daxor and its competitors. For the Medical Devices & Instruments industry, the median ROC (Joel Greenblatt) % is 5.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Daxor's current ROC (Joel Greenblatt) % is %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Daxor stock overvalued right now?
Based on GuruFocus' analysis, Daxor (DXR) is currently considered Possible Value Trap. The stock's GF Value™ is $37.53, compared to a current price of $10.20 — trading 72.8% below its estimated fair value. The current ROC (Joel Greenblatt) % is %. Daxor's overall GF Score™ is 47/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Daxor (DXR), the current ROC (Joel Greenblatt) % is % as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Daxor (DXR) Overvalued in 2026?

Based on GuruFocus' analysis, Daxor stock appears to be undervalued. The current stock price of $10.20 is trading 72.8% below its estimated GF Value™ of $37.53. GuruFocus considers Daxor to be Possible Value Trap.

Key valuation signals for DXR:

  • ROC (Joel Greenblatt) %: %
  • GF Value™: $37.53 vs. price of $10.20 (72.8% below fair value)
  • GF Score™: 47/100 with 1 warning sign

No single metric tells the full story. See the DXR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Daxor Business Description

Other Exchanges DX5:Germany
Address 107 Meco Lane, Oak Ridge, TN, USA, 37830
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system.
47GF Score

Get the complete analysis for DXR

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.20
Price
$37.53
GF Value